Literature DB >> 1379148

Treatment options for the pharmacological therapy of neonatal meningitis.

C M Paap1, J A Bosso.   

Abstract

Neonatal bacterial meningitis has a relatively low incidence in developed countries, but continues to cause morbidity and mortality despite advances in antimicrobial therapy. Bacterial pathogens commonly associated with neonatal meningitis include Group B streptococci, Escherichia coli K1 and other coliforms, Listeria monocytogenes and staphylococci. As it can be difficult to differentiate meningitis from septicaemia in neonates, empirical antibiotic therapy should be effective for both. Selection of an empirical antibiotic regimen should be based on: (a) bacterial prevalence and susceptibility; (b) drug characteristics; (c) postnatal age at the onset of disease; and (d) patient-specific factors. A penicillin in combination with an aminoglycoside or cefotaxime is commonly used in empirical therapies. The increased risk of staphylococcal infection in older neonates requires consideration of an antistaphylococcal antibiotic in the empirical therapy regimen. Once a causative organism has been identified, antimicrobial therapy should be directed towards that pathogen. Duration of therapy remains empirical, but should be at least 7 days for documented bacterial meningitis. Viral meningitis continues to have a high mortality despite the availability of antiviral agents. Adjunctive therapies may further reduce the morbidity and mortality of meningitis. While most of these therapeutic options have not been investigated in neonates, they may prove to be of benefit in the future. Anti-inflammatory agents, such as glucocorticoids, nonsteroidal anti-inflammatory agents and immunoglobulin, may modulate the inflammatory response of a meningeal infection. Other possible therapies in neonatal meningitis include cerebral blood flow modulators and disease prevention with maternal vaccines and perinatal antibiotics. Practical aspects of drug therapy such as route of administration and serum drug concentration monitoring can improve both drug therapy and patient outcome. While antibiotics have greatly improved the treatment outcome of neonatal meningitis, it is clear that additional intervention will be required to increase cure rates and reduce sequelae.

Entities:  

Mesh:

Year:  1992        PMID: 1379148     DOI: 10.2165/00003495-199243050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  48 in total

1.  Potential use of intravenous immune globulin for group B streptococcal infection.

Authors:  C J Baker; F J Noya
Journal:  Rev Infect Dis       Date:  1990 May-Jun

2.  Auditory nerve and brain stem evoked response thresholds in infants treated with gentamicin as neonates.

Authors:  C Adelman; N Linder; H Levi
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-04       Impact factor: 1.547

3.  Routine monitoring of serum vancomycin concentrations: waiting for proof of its value.

Authors:  D J Edwards; S Pancorbo
Journal:  Clin Pharm       Date:  1987-08

4.  Therapeutic problems arising from the use of the intravenous route for drug administration.

Authors:  T Gould; R J Roberts
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

Review 5.  Effect of maturation on drug disposition in pediatric patients.

Authors:  C F Stewart; E M Hampton
Journal:  Clin Pharm       Date:  1987-07

6.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

7.  Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Authors:  R Whitley; A Arvin; C Prober; L Corey; S Burchett; S Plotkin; S Starr; R Jacobs; D Powell; A Nahmias
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

Review 8.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

9.  Transmission of group B streptococci. Traced by use of multiple epidemiologic markers.

Authors:  J D Band; H W Clegg; P S Hayes; R R Facklam; J Stringer; R E Dixon
Journal:  Am J Dis Child       Date:  1981-04

10.  Therapy of bacterial sepsis and meningitis in infants and children: 1989 poll of directors of programs in pediatric infectious diseases.

Authors:  B M Word; J O Klein
Journal:  Pediatr Infect Dis J       Date:  1989-09       Impact factor: 2.129

View more
  3 in total

1.  Efficacy of gatifloxacin in experimental Escherichia coli meningitis.

Authors:  I Lutsar; I R Friedland; H S Jafri; L Wubbel; W Ng; F Ghaffar; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

3.  Clinical Prognosis in Neonatal Bacterial Meningitis: The Role of Cerebrospinal Fluid Protein.

Authors:  Jintong Tan; Juan Kan; Gang Qiu; Dongying Zhao; Fang Ren; Zhongcheng Luo; Yongjun Zhang
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.